AstraZeneca, Daiichi Will Seek Approval Following ADC Trial Success In Advanced Breast Cancer

 
• By Sten Stovall

AstraZeneca and Daiichi said their pivotal Phase II DESTINY-Breast01 trial assessing the HER2-targeting antibody drug conjugate trastuzumab deruxtecan met its primary endpoint, supporting global regulatory submission plans starting in this year’s second half.

Dividing breast cancer cell
Trastuzumab deruxtecan showed a clinically-meaningful response rate in patients with refractory HER2-positive metastatic breast cancer. • Source: Shutterstock

More from Clinical Trials

More from R&D